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ABSTRACT
Epithelioid hemangioendotheliomas (EHEs) are vascular tumors of intermediate 
malignancy that can undergo high-grade malignant transformations. EHEs have 
been characterized by tumor-specific WW domain-containing transcription regulator 
1(WWTR1)-calmodulin-binding transcription activator 1 (CAMTA1) translocations, 
and recently, a novel Yes-associated protein 1 (YAP1)-transcription factor E3 (TFE3) 
gene fusion was identified in EHEs. In this study, we examined the expression levels 
of TFE3 and CAMTA1 via immunohistochemical staining and identified chromosomal 
alterations using fluorescence in situ hybridization (FISH) assays and RT-PCR tests. 
Although all of the EHEs were CAMTA1-positive in immunohistochemical staining, only 
five out of 18 EHEs (27.78%) positively expressed nuclear TFE3. The five TFE3-positive 
EHEs exhibited TFE3 gene break-apart in FISH assays. YAP1-TFE3 gene fusions were 
confirmed by RT-PCR. Interestingly, we observed CAMTA1 gene break-apart in all of 
the five TFE3-positive EHEs via FISH assays, and four out of the five TFE3-positive 
EHEs exhibited WWTR1-CAMTA1 gene fusions via RT-PCR. These results indicate that 
these two chromosomal alterations are not mutually exclusive but compossible in 
EHEs. Finally, primary tumor sites in TFE3-positive EHEs consistently contained single 
masses (P = 0.0359) with larger sizes (P = 0.0550) compared to TFE3-negative 
EHEs. Similar to previous reports, we observed well-formed vessels more frequently 
in TFE3-positive EHEs than in TFE3-negative EHEs (P = 0.0441). In addition, TFE3-
positive EHEs tended to more frequently demonstrate high-grade nuclear atypia (P 
= 0.0654) and hypercellularity (P=0.0987) than TFE3-negative EHEs. Thus, we have 
now established two clinically distinct subgroups of EHEs: TFE3-positive and TFE3-
negative EHEs.
INTRODUCTION
Epithelioid hemangioendotheliomas (EHEs) are 
malignant angiocentric vascular neoplasms composed of 
chains and cords of epithelioid endothelial cells distributed 
in a myxohyaline stroma [1]. EHEs affect patients of all 
ages and arise in virtually any body site. High-risk patients 
with large tumor sizes and frequent mitosis have a poorer 
disease-specific survival of 59% compared to 100% 
survival of patients whose tumors lacked these features 
[2]. 
Several studies have reported an EHE-specific 
translocation resulting in the fusion of the WW domain-
containing transcription regulator 1 (WWTR1) gene 
on 3q23-24 with the calmodulin-binding transcription 
activator 1 (CAMTA1) gene on 1p36 [3-5]. Recently, 
researchers identified a novel fusion between the Yes-
associated protein 1 (YAP1) gene and the transcription 
factor E3 (TFE3) gene, which defined a distinct subset of 
EHEs characterized by somewhat different histological 
morphologies, including focally well-formed vascular 
channels and variably solid architectures, clinically 
occurred in young adults [6, 7]. 
However, it remains unclear if these two distinct 
chromosomal alterations, the WWTR1-CAMTA1 fusion 
and the YAP1-TFE3 fusion specifically, are mutually 
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exclusive in EHEs. In this study, we assess TFE3 
rearrangements in EHEs to verify the newly proposed 
classification system for EHEs and examine the details of 
the clinicopathological characteristics of TFE3 rearranged 
EHEs. 
RESULTS
Clinicopathologic data of EHEs
A total of 18 patients with EHEs (eight men and 
ten women) were included in the study, and the age at 
diagnosis ranged between 23-82 years (mean ± standard 
deviation: 49.89 ± 15.26) (Table 1). Tumors of various 
sizes (4.85 ± 4.77 cm) arose from a variety of organs. 
Eight out of 18 EHEs (44.4%) occurred in the liver, and 
tumors most frequently spread to the lungs (7/8, 87.5%). 
Table 1: Clinical presentation of EHEs
Case Sex/Age Primary site
Tumor 
sizea
(cm)
Multiplicityb Metastatic site Treatment Recurrence
c 
Survival 
(follow-up 
month)
1 M/59 Tongue - d Single - STx No Alive (241)
2 M/26 Liver 1.0 Multiple Lung STx, CTx No Alive (240)
3 M/46 Inguinal area 2.0 Multiple
Lung, lymph 
node, brain, 
breast
STx No Dead (7)
4 M/42 Liver 10.7 Single Lung STx, TACE No Alive (145)
5 M/46 Liver 1.6 Multiple - STx No Alive (105)
6 F/39 Lung 2.8 Single - STx No Alive (95)
7 F/54 Thigh 19.0 Single - STx, RTx No Alive (83)
8 F/57 Axilla 1.5 Single - STx No Alive (75)
9 F/82 Liver 10.8 Multiple - STx, TACE No Alive (73)
10 F/37 Liver 4.2 Multiple Lung STx, CTx No Alive (67)
11 F/35 Liver 3.3 Multiple - STx No Alive (59)
12 F/55 Upper arm 1.9 Single Lung STx, CTx Yes Alive (58)
13 M/51 Liver 4.0 Multiple - STx No Alive (42)
14 F/23 Submandible 1.5 Single - STx No Alive (40)
15 M/70 Lung 6.0 Single
Lymph node, 
liver, adrenal 
gland
STx, RTx No Dead (2)
16 F/69 Parapharynx 3.8 Single - STx Yes Alive (33)
17 M/48 Femur 7.2 Single Stomach, lung
STx, CTx, 
RTx No Alive (32)
18 F/59 Liver 1.2 Multiple Lung STx No Alive (6)
a: Measured the longest diameter of the largest mass when the tumor presented as multiple nodules.
b: Indicates whether single or multiple lesions were present in the primary tumor site at diagnosis.
c: Tumor recurrence observed over a follow-up period of two years.
d: Value could not be determined because an imaging study or mass excision had not been performed.
M: male, F: female.
STx: surgical resection, CTx: chemotherapy, RTx: radiation therapy, TACE: transarterial chemoembolization.
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At diagnosis, eight out of 18 EHEs (44.4%) presented 
as multiple nodules in the primary lesion. Two out of 18 
patients of EHE had tumor recurrence (11.1%) during 
follow-up periods (78.11 ± 16.36 months). 
Upon microscopic examination, many cases were 
composed of chains and cords of epithelioid tumor 
cells distributed in a myxohyaline stroma (Figure 1, 
Supplementary Data 1). All of the tumors showed strong 
expression of CD31 or CD34 via immunohistochemistry, 
indicating that they were vascular tumors. Taken together, 
the diagnoses of these cases were consistent with EHE. 
Next, we performed immunohistochemical staining 
of CAMTA1 and TFE3 (Figure 1 and Table 2). As a result, 
all of the EHEs demonstrated strong nuclear staining of 
CAMTA1. Additionally, TFE3 nuclear expression in 
tumor cells was identified in five out of 18 cases (27.8%). 
As previously described [6, 7, 11], we also found well-
formed vascular channels in the five TFE3-positive 
EHEs on a microscopic examination. Because CAMTA1 
expressions were also observed in the five TFE3-positive 
EHEs at the same time, we decided that other tests were 
necessary to determine expression status of CAMTA1 and 
TFE3 in EHEs.
YAP1-TFE3 gene fusions are compatible with 
WWTR1-CAMTA1 translocations in EHEs
To verify TFE3 gene status, we performed FISH 
assays using TFE3 break-apart probes. We confirmed the 
presence of TFE3 gene translocations in the five EHEs 
that were immunohistochemically TFE3-positive (Figure 
Table 2: Histologic findings and immunohistochemical staining results of EHEs
Case Histologic feature CAMTA1 expression TFE3 expression
1 Spindle cell feature, foamy cytoplasm + -
2 Abundant stroma + -
3 Abundant stroma + -
4 Abundant stroma + +
5 Abundant stroma + -
6 Well-formed blood vessels, spindle cell feature, foamy cytoplasm, mitotic activity (2/10 HPFs), hypercellularity + +
7 Well-formed blood vessels, spindle cell feature, abundant stroma, focal high-grade nuclear atypia, hypercellularity + +
8 Well-formed blood vessels, mitotic activity (1/10 HPFs), hypercellularity + -
9 Abundant stroma, mitotic activity (1/10 HPFs), tumor necrosis + -
10 Abundant stroma, tumor necrosis + -
11 Abundant stroma + -
12 Spindle cell feature, abundant stroma, mitotic activity (1/10HPFs) + -
13 Abundant stroma, mitotic activity (1/10 HPFs), tumor necrosis + -
14 Abundant stroma, mitotic activity (1/10 HPFs), tumor necrosis + +
15 Spindle cell feature, abundant stroma, foamy cytoplasm + -
16 Spindle cell feature, foamy cytoplasm, mitotic activity (1/10 HPFs) + -
17
Abundant stroma, moderate to focal high-grade nuclear 
atypia, foamy cytoplasm, mitotic activity (1/10 HPFs), 
tumor necrosis
+ +
18 Abundant stroma + -
Total 18/18 (100.0%) 5/18 (27.8%)
+: positive, -: negative
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2A, upper panels). To ensure the presence of YAP1-TFE3 
gene fusions, we performed RT-PCR using a YAP1 exon 1 
forward primer and a TFE3 exon 6 reverse primer. YAP1-
TFE3 fusion transcripts were identified in four out of five 
TFE3-positive cases (Figure 2B and Table 3). 
In parallel with the YAP1-TFE3 gene fusion 
assessments, we examined CAMTA1 gene status. As before, 
we performed FISH assays using CAMTA1 break-apart 
probes in five EHEs that were immunohistochemically 
TFE3-positive (Figure 2A, lower panels). Unlike previous 
reports which claimed mutually exclusive occurrence of 
WWTR1-CAMTA1 translocation and YAP1-TFE3 gene 
fusion [6, 7, 11], tumor cells from the TFE3-positive 
EHEs showed separate signals, indicating the presence 
of CAMTA1 translocations. We performed RT-PCR using 
a WWTR1 exon 4 forward primer and a CAMTA1 exon 
9 reverse primer, and, interestingly, four TFE3-positive 
EHEs produced WWTR1-CAMTA1 fusion transcripts 
(Figure 2B and Table 3). Unfortunately, we were unable to 
extract RNA in one last case; thus, we could not evaluate 
the presence of YAP1-TFE3 or WWTR1-CAMTA1 fusions 
via RT-PCR tests in this case.
Next, we examined the 13 EHEs that were 
immunohistochemically TFE3 negative. FISH revealed 
Table 3: Chromosomal alteration of TFE3 and CAMTA1 
Case
TFE3 status CAMTA1 status
FISHa RT-PCRb FISHc RT-PCRd
4 + Unknowne + Unknowne
6 + + + +
7 + + + +
14 + + + +
17 + + + +
a: Interpreted as positive (+) when at least 10 out of 50 tumor cells (20%) 
showed separate green and orange signals using TFE3 break-apart probes.
b: Interpreted as positive (+) when the YAP1-TFE3 fusion transcript was 
observed via RT-PCR.
c: Interpreted as positive (+) when at least 10 out of 50 tumor cells (20%) 
showed separate green and orange signals using CAMTA1 break-apart probes.
d: Interpreted as positive (+) when the WWTR1-CAMTA1 fusion transcript was 
observed via RT-PCR. 
e: Value could not be determined because RNA extraction was failed.
Table 4: Comparison of the clinical presentations of TFE3-positive and TFE3-negative EHEs 
(%) TFE3 (+) EHE TFE3 (-) EHE P-value
Case number 5 13
Age at diagnosis (year) 41.20 ± 5.23 53.23 ± 4.30 0.1383
Sex (Male:Female) 2:3 6:7 1.0000
Follow-up period (month) 79.00 ± 20.44 77.77 ± 37.66 0.9743
Overall survival 5/5 (100.0) 11/13 (84.6) 0.3598a
Tumor size (cm) 8.24 ± 3.14 3.44 ± 0.80 0.0550
Multiplicity 0/5 (0.0) 8/13 (61.5) 0.0359
Local Recurrence b 0/5 (0.0) 2/13 (15.4) 1.0000
Distant Metastasis 2/5 (40.0) 6/13 (46.2) 1.0000
a: A statistical difference of overall survival between patients with TFE3-positive and TFE3-negative EHEs 
by the Kaplan-Meier analysis
b: Tumor recurrence in EHE patients was observed over a follow-up period of two years.
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that break apart occurred only within the CAMTA1 gene 
but not the TFE3 gene in these patients (Supplementary 
Data 2A). We repeatedly attempted to extract mRNA 
from these patients to perform RT-PCR but failed in 7 of 
13 TFE3-negative EHE cases presumably due to mRNA 
degradation of the formalin-fixed, paraffin-embedded 
samples. RT-PCR of the other six cases from which we 
successfully extracted mRNA supported the presence 
of fusion transcripts of WWTR1-CAMTA1 genes but not 
YAP1-TFE3 genes (Supplementary Data 2B).
Figure 1: Histological features and immunohistochemical expression profiles of TFE3-positive EHEs. EHEs composed of 
vasoformative CD31-positive epithelioid tumor cells in a myxohyalinestroma (upper two lanes). Five out of 18 EHEs demonstrated strong 
simultaneous nuclear expression of CAMTA1 and TFE3 (lower two lanes, respectively). 200× magnification.
Figure 2: CAMTA1 translocation in EHEs with TFE3 rearrangements. A. FISH assay results for TFE3 and CAMTA1 break-
apart showing separated green and orange signals (1,000× magnification). B. RT-PCR assay results identifying YAP1-TFE3 (556 bp, left 
panel) and WWTR1-CAMTA1 fusion transcripts (400 bp, right panel). N/C, negative control.
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Comparison of the clinical and histologic 
presentation of TFE3-positive and TFE3-negative 
EHEs
Using immunohistochemistry, the clinical features 
of five TFE3-positive EHEs were compared to those of 
13 TFE3-negative EHEs (Table 4). At diagnosis, patients 
with TFE3-positive EHEs tended to be younger (41.20 
± 5.30 years) than patients with TFE3-negative EHEs 
(53.23 ± 4.30 years, P = 0.1383). Additionally, the longest 
diameter of single tumor size was much larger in TFE3-
positive EHEs (8.24 ± 3.14 cm) compared with TFE3-
negative EHEs (3.44 ± 0.80 cm, P = 0.0550). Although 
TFE3-negative EHEs demonstrated small tumor sizes, 
they were more likely to present multiple lesions in the 
primary tumor site whereas TFE3-positive EHEs exhibited 
a single lesion (P = 0.0359). 
In the TFE3-positive group, no local recurrence 
(0.0%, n = 0/5) occurred, but two distant metastases 
(40.0%, n = 2/5) developed. Meanwhile, in the TFE3-
negative group, two local recurrences (15.4%, n = 2/13), 
and six distant metastases (53.9%, n = 6/13) developed. 
No statistically significant difference was observed in the 
rate of local recurrence (P = 1.0) and distant metastatic 
(P = 1.0) between TFE3-positive and TFE3-negative 
EHEs (Table 4). When we compared the overall survival 
between patients with TFE3-positive and TFE3-negative 
EHEs by Kaplan-Meier analysis, there was no statistically 
significant difference (Supplementary Data 3; P = 0.3598).
We compared the histologic features of EHE 
cases according to their TFE3 expression state but 
observed varying degrees of myxohyalinized stroma, 
tumor necrosis, mitotic activity, spindle and epithelioid 
cytologic features, and foamy and eosinophilic cytoplasm 
that seemed irrelevant to their TFE3 expression (P > 0.05, 
Table 5 and Supplementary Data 1). Similar to previous 
reports [6, 7], we observed well-formed vessels more 
frequently in TFE3-positive EHEs than in TFE3-negative 
EHEs (P = 0.0441). In addition, TFE3-positive EHEs 
tended to more frequently demonstrate high-grade nuclear 
atypia (P = 0.0654) and hypercellularity (P = 0.0987) than 
TFE3-negative EHEs, although the difference did not 
reach statistical significance.
DISCUSSION
In this study, we examined the TFE3 and CAMTA1 
protein expression profiles via immunohistochemistry 
and assessed the chromosomal alterations of TFE3 and 
CAMTA1 via FISH assays in EHEs. We also verified the 
presence of YAP1-TFE3 and WWTR1-CAMTA1 fusion 
transcripts by RT-PCR. These results indicate that these 
two chromosomal alterations were not mutually exclusive 
but compossible in EHEs. Therefore, we classified EHEs 
into two subgroups: TFE3-positive and TFE3-negative 
EHEs, and compared the clinical and histologic features 
of each. Notably, TFE3-positive EHEs seemed to present 
as a single larger mass compared with TFE3-negative 
EHEs. Similar to a previous report [6], we also observed 
an earlier onset of disease in patients with TFE3-positive 
EHEs than in patients with TFE3-negative EHEs and 
well-formed vascular channels in TFE3-positive EHEs 
on histological examination. In addition, we observed a 
tendency for TFE3-positive EHEs to more frequently 
demonstrate high-grade nuclear atypia and hypercellularity 
than TFE3-negative EHEs.
A previous study examined CAMTA1 expression 
profiles in EHEs and identified strong nuclear expression 
in most cases [8]. Consistent with these findings, we also 
demonstrated strong nuclear expression of CAMTA1 in 
100.0% of EHEs. In the current study, we were able to 
identify TFE3 nuclear expression in five out of 18 cases 
(27. 8%). This ratio is much lower compared with that of 
a previous article which claimed to have observed TFE3 
nuclear reaction in as much as 87.5% (n = 21/24) in their 
EHEs study population [7]. Our data also differs in that 
they reported TFE3 rearrangement to occur in merely two 
Table 5: Comparison of the histologic features of TFE3-positive and TFE3-negative EHEs 
(%) TFE3 (+) EHE TFE3 (-) EHE P-value
Case number 5 13
Presence of spindle cytologic feature 2/5 (40.0) 4/13 (30.8) 1.0000
Presence of foamy/feathery cytoplasm 2/5 (40.0) 4/13 (30.8) 1.0000
Presence of high-grade nuclear atypia 2/5 (40.0) 0/13 (0.0) 0.0654
Presence of mitosis 3/5 (60.0) 5/13 (38.5) 0.6078
Presence of hypercellularity 3/5 (60.0) 2/13 (15.4) 0.0987
Presence of well-formed blood vessels 3/5 (60.0) 1/13 (7.7) 0.0441
Abundant stroma 3/5 (60.0) 9/13 (69.2) 1.0000
Tumor necrosis 2/5 (40.0) 3/13 (23.1) 0.5827
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cases (5.7%, n = 2/35) [7], whereas we detected YAP1-
TFE3 gene fusion in 22.2% (n = 4/18) of EHEs and 80.0% 
(n = 4/5) of TFE3-positive EHEs based on FISH and RT-
PCR results. EHE remains an extremely rare disease entity 
of which TFE3 expression has been scarcely examined. 
Although we add our current observations to the limited 
literature covering this subject, we acknowledge that 
subsequent studies which cover more cases are still 
required to further clarify such discrepancies, especially 
on TFE3 expression profile and YAP1-TFE3 gene fusion 
status that exist between our data and the previous report 
[7].
WWTR1 and YAP1 share conserved amino acid 
sequences for the WW domain that can interact with 
PDZ domains. They are named for the shared homology 
observed in postsynaptic density protein 95 (PSD95), 
Drosophila discs large tumor suppressor (Dlg1), and 
zonula occludens-1 protein (zo-1) [9]. Recently, a study 
described the mechanism of action of a WWTR1(TAZ)-
CAMTA1 fusion oncoprotein, and the results suggested 
that the WWTR1-CAMTA1 fusion might cause resistance 
to anoikis and the oncogenic transformation of tumor cells 
[10]. This study implies that the WWTR1(TAZ)-CAMTA1 
fusion oncoprotein might have a profound role in the 
molecular pathogenesis of EHEs. Despite the careful 
analyses reported in previous studies [6, 7, 11], questions 
still remain regarding how two very similar molecules 
could have different translocation partners in one specific 
tumor type. This concept will be examined in more detail 
in future studies. 
In this study, we observed that TFE3-positive 
EHEs had a tendency to present as a single larger mass 
in younger patients compared with TFE3-negative EHEs 
and demonstrated histologic findings of the presence of 
high-grade nuclear atypia and hypercellular areas. We 
believe that these clinicopathologic findings in EHEs 
with both WWTR1-CAMTA1 and YAP1-TFE3 gene 
translocations, which were not identified in EHEs having 
only the WWTR1-CAMTA1 translocation, might reflect a 
higher degree of genetic heterogeneity in these tumors. 
Traditionally, sarcomas have been classified into two 
broad categories: tumors with simple genetic alterations 
and tumors with complex and unbalanced karyotypes 
[12]. Tumors with complex genetic alterations are typified 
by genome instability, resulting in multiple genomic 
aberrations in the genome of a single tumor and the 
heterogeneity of aberrations across tumors of a given type 
[13, 14]. Although two distinct chromosomal alterations 
specific to EHEs have been identified, we presume that 
these two genetic alterations can occur simultaneously in 
EHEs, possibly reflecting an increased degree of genetic 
instability.
According to a previous study, tumor size was 
associated with decreased survival of EHE patients and 
tumors with >3 mitotic figures/50 high power fields and 
size >3.0 cm had the worst prognosis [2]. Interestingly, 
we observed that TFE3-positive EHEs presented as single 
masses with significantly larger sizes compared to TFE3-
negative EHEs, which typically contained multiple lesions 
of smaller sizes. These data, together with the above 
findings, have newly established two clinically distinct 
subgroups of EHEs: TFE3-positive and TFE3-negative 
EHEs, which can be used to more accurately diagnose and 
treat EHEs in the future.
MATERIALS AND METHODS
Cases
This retrospective study was approved by the 
Institutional Review Board of Yonsei University Medical 
Center (approval number: 4-2014-0852). Our inclusion 
criteria defined a study population of 18 EHE patients 
who had been histologically diagnosed between 1993-
2013. Archival tissues stained with hematoxylin and eosin 
(H&E) were reviewed by three pathologists (SK Kim, SJ 
Lee, and WI Yang).
Immunohistochemistry
Tumors were fixed in formalin and embedded in 
paraffin. Briefly, 5 μm-thick sections were cut using a 
microtome, transferred onto adhesive slides, and dried at 
62°C for 30 min. Immunohistochemistry with antibodies 
against CD31 (M0823, Dako, CA, USA), CD34 (M7165, 
Dako, CA, USA), TFE3 (MRQ-37, CA, USA), and 
CAMTA1 (ab64119, Abcam, Cambridge, UK) was 
performed using an automated immunohistochemical 
staining instrument (Ventana Discovery® XT, Ventana 
Medical System, AZ, USA).
Fluorescent in situ hybridization (FISH) assay
FISH was performed on tumor sections after 
examination by H&E microscopy. A ZytoLight SPEC 
TFE3 Dual Color Break-Apart Probe (Z-2109-200, 
ZytoVision GmbH, Bremerhaven, Germany) and a 
MacProbeTM CAMTA1 Dual Color Break-Apart Probe 
(KH01M2NA12 and KH02M2NA12, Macrogen, South 
Korea) were used according to the manufacturer’s 
instructions for the detection of translocations involving 
the TFE3 gene at Xp11.23 and the CAMTA1 gene at 
1p36.23, respectively. Break-apart on the slides was 
evaluated using an epifluorescence microscope (Olympus, 
Tokyo, Japan). During interphase in normal cells without 
translocations, green/orange fusion signals appear. 
Xp11.23 or 1p36.23 loci affected by translocations 
are indicated by separate and distinct green and orange 
signals. A case was interpreted as positive when at least 
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10 out of 50 counted tumor cells (20%) showed separated 
green and orange signals [7]. 
Reverse transcription polymerase chain reaction 
(RT-PCR)
Isolation of RNA from formalin-fixed, paraffin-
embedded (FFPE) samples was performed following 
the manufacturer’s protocol (RNeasy FFPE kit, Qiagen, 
Valencia, CA). RT-PCR was performed as previously 
published [3, 6, 7] using the following primers to 
identify the WWTR1-CAMTA1 fusion transcript or 
the YAP1-TFE3 fusion transcript: WWTR1 exon 4 
forward, 5’-CCGTCAGTTCCACACCAGTGCCTC-3’; 
CAMTA1 exon 9 reverse, 
5’-GGGGCTACAGCAGGGGAGGC-3’; YAP1 exon 1 
forward, 5’-CCTGGAGGCGCTCTTGAACG-3’; TFE3 
exon 6 reverse, 5’-GTTGCTGACAGTGATGGCTGG3’. 
The RT-PCR products were analyzed by electrophoresis.
Statistics
All statistical analyses were performed using 
GraphPad Prism 5 software, version 5.01 (GraphPad 
Software Inc., La Jolla, CA, USA) and SPSS for Windows, 
version 20.0 (SPSS Inc., Chicago, IL, USA). For the 
analysis of age at diagnosis and tumor size, a significant 
difference between means was determined by t-tests. Sex, 
tumor multiplicity, and metastasis were compared by Chi-
square analyses and Fisher’s exact tests. 
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